ClinicalTrials.gg
Not yet recruitingNCT07357649BAR-RAUpdated Jan 22, 2026

Baricitinib Effects on Procoagulant State in Rheumatoid Arthritis

A Phase 4 interventional study of Baricitinib in Rheumatoid Arthritis, sponsored by Tanta University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by Tanta University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies testing baricitinib in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, 1 of them phase 3. baricitinib · Arthritis, Rheumatoid.

Planned enrollment
16th of 23
100 · median 290
Started
2026
the only one that year
Phase 4
9 of 23
3 open now
Registered
23rd of 23
by date
Lead sponsor
1 of 23
Tanta University

Among the 23 studies testing baricitinib in Arthritis, Rheumatoid, this one is the 16th largest by planned enrollment, is the only one that started in 2026, is one of 9 in phase 4, and was the 23rd registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 23 studies testing baricitinib in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About baricitinib

baricitinib: first FDA approval 2018 (OLUMIANT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing baricitinib in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This prospective interventional study aims to evaluate the effects of baricitinib on disease activity, lipid profile, atherogenic index, and procoagulant biomarkers including monocyte-derived human tissue factor and D-dimer in patients with rheumatoid arthritis, compared with conventional therapy.

Read the detailed description

Rheumatoid arthritis is a chronic systemic inflammatory disease associated with increased cardiovascular and thrombotic risk. Baricitinib, a Janus kinase 1 and 2 inhibitor, is approved for the treatment of moderate to severe rheumatoid arthritis; however, concerns remain regarding its potential prothrombotic effects.

In this prospective study, patients with rheumatoid arthritis will be recruited from Tanta University Hospitals and allocated into two parallel groups. The intervention group will receive baricitinib in combination with methotrexate after failure of conventional therapy, while the control group will continue conventional treatment.

Clinical assessment, disease activity score (DAS28), functional status (MHAQ), lipid profile, atherogenic index, monocyte-derived human tissue factor, and D-dimer levels will be evaluated at baseline and after three months to assess thrombotic risk and cardiovascular safety.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged ≥ 18 years.
  • Diagnosis of rheumatoid arthritis according to the ACR/EULAR 2010 criteria.
  • Patients with active rheumatoid arthritis despite conventional treatment.
  • Ability to provide written .

Exclusion criteria

Exclusion Criteria:

  • Presence of other diseases.
  • Diabetes mellitus.
  • Dyslipidemia or use of lipid-lowering therapy within the last 6 months.
  • Chronic kidney disease.
  • Chronic liver disease.
  • Chronic respiratory disease.
  • History of .
  • Pregnancy or breastfeeding.
  • Alcohol or drug abuse.
  • Acute or chronic infection.
  • Current prednisone dose > 7.5 mg/day.
  • History of arterial or venous thrombosis.
  • Use of anticoagulant or antithrombotic drugs within the last 3 months.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Baricitinib

    Drug: Baricitinib

  • No intervention
    Conventional DMARD therapy

Interventions

  • Oral baricitinib administered in combination with methotrexate according to standard clinical practice

06

What researchers measure

Primary outcomes

  1. Change in Monocyte-Derived Human Tissue Factor Level

    Change in tissue factor level from baseline to 3 months after initiation of baricitinib therapy.

    Time frame: Baseline and 3 months

Secondary outcomes

  1. Change in Disease Activity Score (DAS28)

    Change in DAS28 from baseline to 3 months.

    Time frame: Baseline and 3 months

  2. Change in Total Cholesterol Level

    Change in total cholesterol level from baseline to 3 months.

    Time frame: Baseline and 3 months

  3. Change in Triglyceride Level

    Change in triglyceride level from baseline to 3 months.

    Time frame: Baseline and 3 months

  4. Change in HDL-Cholesterol Level

    Change in HDL-C level from baseline to 3 months.

    Time frame: Baseline and 3 months

  5. Change in LDL-Cholesterol Level

    Change in LDL-C level from baseline to 3 months

    Time frame: Baseline and 3 months

  6. Change in Atherogenic Index (TC/HDL-C)

    Change in atherogenic index from baseline to 3 months.

    Time frame: Baseline and 3 months

  7. Change in D-dimer Level

    Change in D-dimer level from baseline to 3 months.

    Time frame: Baseline and 3 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Apr 2026, 3 months later.

Of 79 non-industry phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 92. This study's planned 3 months is below that.

Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2026
First posted
Jan 22, 2026
StartEst.
Jan 2026
Primary completionEst.
Apr 2026
CompletionEst.
Dec 2026
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07357649
Lead sponsor
Tanta University
Responsible party
Nourhan Elsaeed Abdelmabod Elhaish (Principal Investigator, Tanta University) — Principal investigator
First posted
Jan 22, 2026
Start date
Jan 2026 (estimated)
Primary completion
Apr 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion